Advance your CAR-T program with NeoGenomics’ broad solutions of assay technologies

Equipped with advanced genomic analysis tools and years of experience working with clients engaged in early discovery, pre-clinical safety, and clinical trials, NeoGenomics’ expertise combined with a broad technology menu enables us to help accelerate and streamline your cell and gene therapy development efforts.

Why CAR/TCR is Important:

Adoptive T cell therapies are making important contributions to immunotherapy and precision medicine; Chimeric Antigen Receptor-T (CAR-T) cell therapies are perhaps the best-known example especially with the remarkable success in the treatment of refractory hematological malignancies. T cell receptors or TCRs are also showing real promise for these applications with the potential to also provide durable clinical response for other types of cancer, especially solid tumor, with less therapy-associated toxicities.

How it works:

Chimeric antigen receptor and T-cell receptor (CAR-T/TCR-T) immunotherapies are specific targeted cellular therapies that exploit the cytotoxic potential of T cells to kill cancer cells in an antigen-specific manner. Briefly, the approach involves genetic modification of isolated T cells from a patient to express the desired CAR or TCR gene on cells’ surface, these modified T cells are then infused back into the patient, where they eventually come in direct contact with the cancer antigen, resulting in the killing of the cancer cell.

CAR-T cells are an attractive therapeutic approach in that they can specifically recognize antigens on the surface of cancer cells via an extracellular single-chain fragment variable (scFv) domain, which upon engagement with the cancer antigen results in immobilization and clustering of CARs and formation of what’s referred to as the “non-classical immune synapse”, an immunological synapse formed between an activated T‐cell and a target cancer cell to successfully commit cytotoxic immune function. TCR-T cells instead use the TCR to recognize cancer-associated antigens in the context of the major histocompatibility complex-I (MHC-I). TCRs can specifically recognize cancer-associated peptides in the context of MHC-I and activate the T cell upon engaging with the complex. The activated T-cells can then stimulate an anti-tumor response.

The field of CAR-T/TCR-cellular therapies is still maturing, but preclinical and clinical studies have already shown remarkable results and is certainly going to lead to the development of approved personalized therapeutic options in the future.

Assay platforms and applications (to name a few)

Flow Cytometry

  • Target cell viability
  • Target phenotyping
  • Activation state


  • Biodistribution
  • Gene vector copy number
  • Gene expression profiling

Spatial analysis

  • MultiOmyx Phenolmager® or GeoMx®DSP
  • Spatial Transcriptomics (Toxicity)
  • Immune phenotyping (Exhaustion and Immunosuppressive phenotypes)
  • Comprehensive Tumor Micro-Environment (TME) analysis

Next-gen sequencing

Custom assay development

nCounter CAR-T characterization panel

  • TCR diversity
  • Profile signaling pathways
  • Antigen presentation and processing

Immunohistochemistry (IHC)

  • Biomarker testing
  • Patient selection
CAR-T image

Thank you for your interest in our CAR-T solution offerings.
We would like to learn more about your CAR-T therapy targets and Immuno-Oncology needs to better serve you. Please kindly fill out the form below and a NeoGenomics’ team member will be in contact with you shortly.

Which research area are you currently working in and/or interested in? (Select all that apply)
What CAR-T applications are you looking to onboard? (Select all that apply)
Which tumor type is your CAR-T cell therapy target aiming for? (Select all that apply)
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.